[250 Pages Report] As per Future Market Insights’ latest industry analysis, the valuation for the global implantable collamer lens market was around US$ 212.9 Mn in 2021. Sales are projected to grow at a 13.1% CAGR over the forecast period, with the market valuation reaching US$ 838.2 Mn in 2032.
| Attributes | Key Insights |
| Implantable Collamer Lens Market Base Year Value (2021) | US$ 212.9 Mn |
| Estimated Market Size (2022) | US$ 244.8 Mn |
| Projected Market Valuation (2032) | US$ 838.2 Mn |
| Value-based CAGR (2022-2032) | 13.1% |
| Key Market Players | STAAR SURGICAL |
Since phakic intraocular implants were approved two decades ago, refractive surgeons have chosen to utilize them to treat myopia that is unresponsive to excimer laser treatment. A posterior chamber phakic intraocular lens (IOL) created and produced by STAAR Surgical, the Visian Implantable Collamer Lens (ICL), was FDA approved in 2005 and has been demonstrated to be effective in the correction of myopia up to 18.00 D.
Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15174
The ICL was only offered in the U.S. in a spherical variant until 2018. As a result, high astigmatism and high myopia could not be treated simultaneously. In light of this, several surgeons in the refractive fiend adopted a sequential operation strategy that employs the use of an excimer-laser enhancement after ICL implantation. This sequence has been referred to as “Bioptics”.
The use of ICL in refractive surgery is increasing. ICLs are often regarded as an alternative to laser-based corneal procedures such as LASIK and photorefractive keratectomy (PRK). The implantable collamer lens is a specific type of posterior chamber phakic intraocular lens (pIOL). High levels of refractive error or situations where corneal refractive surgery is not recommended call for the adoption of pIOL. Quicker healing and reversibility are the additional benefits of this procedure over corneal refractive surgery.
High incidence of cataracts and other vision impairments among elderly and diabetic individuals is underpinning the need for implantable collamer lens. In addition to this, rising healthcare costs, and government-backed investments for the construction of healthcare infrastructure are some of the key factors propelling the market.
“Growing prevalence of refractive disorders, and the emergence of alternatives to laser techniques for refractive correction are underpinning the demand for implantable collamer lens,” says and FMI analyst.
Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15174
Key Takeaways:
- By indication, sales in the myopia segment are slated to increase at a 12.6% CAGR through 2032.
- In terms of end user, demand in the hospitals segment will grow at a 7% CAGR during the forecast period.
- China accounted for 6% of the total market share in 2021 and the trend is expected to continue over the assessment period.
- The U.S. will continue dominating the North America implantable collamer lens market through 2032.
- Japan will emerge as a lucrative pocket in the East Asia implantable collamer lens market.
Competition Landscape
The global implantable collamer lens market includes only one manufacturer known as STAR SURGICAL. Incorporated in 1982 for the purpose of developing, producing, and marketing implantable lenses, the company is the first to receive the U.S. FDA approval for implantable collamer lens. Some recent developments include:
- In April 2021, STAAR submitted clinical data to the FDA to support a marketing approval for their EVO family of myopia lenses. The submission remains under interactive review with the FDA.
Request Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-15174
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the implantable collamer lens market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.
The research study is based on the indication (myopia, hyperopia, and astigmatism), and end user (hospitals, ophthalmic clinics, ambulatory surgical centers, and eye research institutes), across seven key regions.
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedIn| Twitter| Blogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com